Core Viewpoint - Dogwood Therapeutics, Inc. is advancing its clinical trials and expanding its pipeline with a focus on pain management and neuropathy, reporting significant financial results for Q3 2025, including a notable increase in research and development expenses due to new initiatives and partnerships [2][3][5]. Financial Performance - Research and development expenses for Q3 2025 were $14.5 million, a substantial increase from $0.5 million in Q3 2024, primarily due to $12.0 million in acquired in-process research and development expenses related to the licensing of SP16 and increased clinical trial costs [3]. - General and administrative expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, attributed to lower legal and accounting fees [4]. - The net loss attributable to common stockholders for Q3 2025 was $15.7 million, or $8.20 per share, compared to a net loss of $2.3 million, or $2.05 per share, in Q3 2024 [5]. Clinical Development - The company has enrolled 100 patients in the ongoing Halneuron Phase 2b trial, with 80 patients completing treatment, and plans to release an interim analysis in Q4 2025 [9]. - Halneuron is a non-opioid analgesic in Phase 2b development for chemotherapy-induced neuropathic pain, having received fast track designation from the FDA [7]. - SP16, a new pipeline asset, is a first-in-class candidate aimed at treating cancer-related pain and is fully funded for its Phase 1b study by the National Cancer Institute [2][10]. Pipeline Overview - The research pipeline includes two first-in-class candidates: Halneuron and SP16 IV, targeting pain and neuropathic disorders [6]. - SP16 IV acts as an LRP1 agonist, showing potential for anti-inflammatory effects and nerve damage repair in preclinical studies [8].
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results